Logo

Incyte Announces $422 Million Private Placement

Feb 25, 2000
Premium

P

ALO ALTO, Calif.--Incyte Pharmaceuticals said it has entered into a definitive purchase agreement for the sale of two million shares of newly issued common stock to selected institutional investors for $422 million. Purchase price will be $211 per share. The company said net proceeds will be used for working capital and general corporate purposes as well as to make strategic investments, acquire or license technology or products, or acquire complementary businesses.

Filed under

Informatics
Breaking News
The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.